[{"data":1,"prerenderedAt":152},["ShallowReactive",2],{"drug-lasmiditan":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":67,"warnings":68,"renal":76,"monitoring":77,"interactions":78,"review":79,"examples":82,"atc":88,"iran":90,"usApproval":97,"links":103,"populations":117},"lasmiditan",1,{"fa":7,"en":8},"لاسمیدیتان","Lasmiditan","nervous-system",{"fa":11,"en":12},"آگونیست 5-HT1F (دیتان)","5-HT1F agonist (ditan)",[14],{"name":15,"market":16},"Reyvow","US",[18,19,7],"reyvow","ری‌وو",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-50","tablet","oral","50 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},50,"mg",false,[16],[32],{"source":33,"section":34},"fda-reyvow","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-100","100 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},100,[16],[42],{"source":33,"section":34},[44],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":57,"notes":60},"acute","migraine-acute",{"fa":48,"en":49},"حمله حاد میگرن بزرگسال — ۵۰، ۱۰۰ یا ۲۰۰ mg در صورت نیاز","Acute migraine, adults — 50, 100 or 200 mg as needed",{"minAge":51},{"value":52,"unit":53},18,"year","fixed",{"perDose":27,"perDoseMax":56,"dosesPerDay":5},200,[58],{"source":33,"section":59},"2",[61],{"text":62,"refs":65},{"fa":63,"en":64},"حداکثر یک دوز در ۲۴ ساعت؛ تا ۸ ساعت پس از مصرف رانندگی نکند. دوز دوم برای همان حمله مؤثر نیست.","No more than one dose in 24 h; do not drive for 8 h after. A second dose for the same attack is not effective.",[66],{"source":33,"section":59},[],[69],{"text":70,"refs":73},{"fa":71,"en":72},"اختلال رانندگی؛ تضعیف CNS (سرگیجه، خواب‌آلودگی)؛ سندرم سروتونین؛ سردرد ناشی از مصرف زیاد دارو.","Driving impairment; CNS depression (dizziness, sedation); serotonin syndrome; medication-overuse headache.",[74],{"source":33,"section":75},"5",[],[],[],{"status":80,"reviewer":81,"date":81},"unverified",null,[83],{"regimen":45,"formulation":22,"input":84,"expect":87},{"ageYears":85,"weightKg":86},35,65,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":56},[89],"N02CC08",{"status":91,"refs":92},"not-found",[93],{"source":94,"section":95,"url":96},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Lasmiditan",{"kind":98,"refs":99,"id":102},"NDA",[100],{"source":33,"section":101},"SPL approval \u002F marketing category","NDA211280",[104,107,111,114],{"kind":105,"url":106,"label":102},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=211280",{"kind":108,"url":109,"label":110},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=aea3358c-ff41-4490-9e6d-c7bf7b3de13f","FDA Reyvow",{"kind":112,"url":113,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa620015.html",{"kind":115,"url":116,"label":89},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N02CC08",{"pregnancy":118,"lactation":127,"pediatric":135,"geriatric":144},{"level":119,"text":120,"quote":123,"refs":124},"caution",{"fa":121,"en":122},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with the use of REYVOW in pregnant women.",[125],{"source":33,"section":126},"8.1",{"level":119,"text":128,"quote":131,"refs":132},{"fa":129,"en":130},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of lasmiditan in human milk, the effects of lasmiditan on the breastfed infant, or the effects of lasmiditan on milk production.",[133],{"source":33,"section":134},"8.2",{"level":136,"text":137,"quote":140,"refs":141},"not-established",{"fa":138,"en":139},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[142],{"source":33,"section":143},"8.4",{"level":119,"text":145,"quote":148,"refs":149},{"fa":146,"en":147},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",[150],{"source":33,"section":151},"8.5",1792191551504]